Dynogen Pharmaceuticals, Inc.

Astellas is to close down a small research subsidiary in the US by the end of this year, as it looks to control costs and rationalise its corporate R&D effort. The centre in Durham, North Carolina was

Regulatory risk and a mature market for some indications have driven Big Pharma players from the GI space. That signals possible biotech opportunity. Stretched to its full length, the adult gastrointe

Crunched credit wiped out many biotech firms in 2009, yet some emerged from the wreckage leaner and stronger. How did they do it, asks Dr Sukaina Virji-Jeganathan. Despite hints of the emergence of g

Alnara Pharmaceuticals, a US company developing non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, has appointed Dr Lee Brettman to the newly created position